| Not Yet Recruiting | A Study of VG712 in Patients With Mycosis Fungoides NCT07529405 | Virogen Biotechnology Inc. | Phase 2 |
| Not Yet Recruiting | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Thera NCT07213882 | Assistance Publique - Hôpitaux de Paris | EARLY_Phase 1 |
| Recruiting | A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Exp NCT07055477 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance NCT07132567 | Kyowa Kirin Co., Ltd. | — |
| Recruiting | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL NCT06470451 | Soligenix | Phase 3 |
| Completed | IL-35: A Key Immunosuppressive Driver in Mycosis Fungoides Modulated by Phototherapy NCT07235813 | Kasr El Aini Hospital | N/A |
| Recruiting | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Withdrawn | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphom NCT05538988 | AHS Cancer Control Alberta | Phase 1 / Phase 2 |
| Recruiting | Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis NCT06207812 | M.D. Anderson Cancer Center | — |
| Suspended | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) NCT06235281 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Active Not Recruiting | Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome NCT05944562 | Washington University School of Medicine | Phase 1 |
| Recruiting | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma NCT06508463 | Mayo Clinic | Phase 1 |
| Recruiting | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma NCT04234048 | SciTech Development, Inc. | Phase 1 |
| Completed | Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light NCT05872854 | Ellen Kim, MD | Phase 2 |
| Recruiting | A Registry for People With T-cell Lymphoma NCT05978141 | Memorial Sloan Kettering Cancer Center | — |
| Unknown | Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides NCT05838599 | Northwestern University | EARLY_Phase 1 |
| Terminated | Ritlecitinib in CTCL NCT05879458 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Unknown | Histopathological Changes in Mycosis Fungoides NCT05904522 | Bezmialem Vakif University | N/A |
| Recruiting | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides NCT05414500 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients NCT06421571 | National and Kapodistrian University of Athens | — |
| Unknown | Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study NCT05855460 | Cairo University | — |
| Unknown | Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides NCT05526638 | Cairo University | N/A |
| Recruiting | Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quar NCT05357794 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell NCT04118868 | Sorrento Therapeutics, Inc. | Phase 1 |
| Completed | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Of NCT06782854 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Not Yet Recruiting | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides NCT05205902 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Suspended | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL NCT05138458 | Myeloid Therapeutics | Phase 1 / Phase 2 |
| Completed | Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides NCT05303480 | Centre for Human Drug Research, Netherlands | N/A |
| Completed | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat NCT04955340 | 4SC AG | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome NCT04960618 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Photopheresis in Early-stage Mycosis Fungoides NCT05680558 | Columbia University | Phase 2 |
| Terminated | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides NCT04676087 | Emory University | Phase 1 / Phase 2 |
| Terminated | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogam NCT04541017 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. NCT04904146 | Lund University Hospital | — |
| Withdrawn | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma NCT02301494 | Rochester General Hospital | N/A |
| Recruiting | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome NCT04256018 | Stanford University | Phase 2 |
| Completed | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Ad NCT04185220 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides NCT03695471 | Mayo Clinic | Phase 2 |
| Terminated | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides NCT03789864 | Indiana University | N/A |
| Completed | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancie NCT03905135 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL NCT03602157 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Withdrawn | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients NCT03288818 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Recruiting | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients NCT03587844 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma NCT02341209 | Rochester General Hospital | Phase 2 |
| Recruiting | Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides NCT03398161 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Mechlorethamine Induced Contact Dermatitis Avoidance Study NCT03380026 | Rochester Skin Lymphoma Medical Group, PLLC | Phase 2 |
| Terminated | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL NCT02811783 | Elorac, Inc. | Phase 3 |
| Unknown | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides NCT02943642 | Angimmune LLC | Phase 2 |
| Completed | TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome NCT02822586 | Virginia Commonwealth University | Phase 1 |
| Completed | Cell-free Circulating DNA in Primary Cutaneous Lymphomas NCT02883517 | University Hospital, Bordeaux | — |
| Completed | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrom NCT02953301 | 4SC AG | Phase 2 |
| Recruiting | ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome NCT02848274 | Stanford University | — |
| Terminated | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis NCT02890368 | Pfizer | Phase 1 |
| Unknown | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis NCT02881749 | Thomas Jefferson University | Phase 2 |
| Completed | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715 | Mayo Clinic | N/A |
| Unknown | NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) NCT02542124 | Neumedicines Inc. | Phase 2 |
| Unknown | Vietnam Cryptococcal Retention in Care Study - Version 2.1 NCT03267407 | National Hospital for Tropical Diseases, Hanoi, Vietnam | — |
| Terminated | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgki NCT01609816 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Completed | Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnos NCT02296164 | Helsinn Therapeutics (U.S.), Inc | — |
| Terminated | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas NCT02323659 | Polish Lymphoma Research Group | Phase 4 |
| Completed | Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Periph NCT01590732 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Parti NCT01578499 | Millennium Pharmaceuticals, Inc. | Phase 3 |
| Terminated | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing NCT01556828 | Stanford University | — |
| Active Not Recruiting | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomato NCT01352520 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level NCT01396070 | Youn Kim | Phase 2 |
| Completed | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma NCT01134341 | Acrotech Biopharma Inc. | Phase 1 |
| Terminated | Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides NCT00985140 | Stanford University | — |
| Completed | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) NCT00611208 | Angimmune LLC | Phase 2 |
| Completed | An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis F NCT00535470 | Yaupon Therapeutics | Phase 2 |
| Terminated | Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma NCT01445340 | National Cancer Institute (NCI) | Phase 1 |
| Completed | T Cell Repertoire Analysis of Immune Mediated Skin Diseases NCT00368784 | University of California, Davis | — |
| Completed | Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides NCT00168064 | Yaupon Therapeutics | Phase 2 |
| Completed | Effect of Denileukin Diftitox on Immune System in CTCL Patients NCT00254332 | University of Pittsburgh | — |
| Unknown | Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome NCT00157274 | Latin American Cooperative Onco-Haematology Group - Peru | Phase 2 |
| Terminated | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome NCT00127881 | Emergent Product Development Seattle LLC | Phase 3 |
| Completed | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL NCT00178841 | Vanderbilt University | Phase 2 |
| Withdrawn | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Pati NCT00226993 | Stanford University | Phase 1 / Phase 2 |
| Completed | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) NCT00091559 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research NCT00177268 | University of Pittsburgh | — |
| Completed | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas NCT00185965 | Ronald Levy | Phase 1 / Phase 2 |
| Completed | Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungo NCT00221039 | M.D. Anderson Cancer Center | Phase 4 |
| Completed | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome NCT00047060 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Completed | In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) NCT00177190 | University of Pittsburgh | — |
| Terminated | Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides NCT00496743 | Bispebjerg Hospital | N/A |
| Terminated | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions NCT00129415 | University of Michigan | Phase 1 / Phase 2 |
| Completed | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients NCT00051012 | Eisai Inc. | Phase 4 |
| Completed | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients NCT00050999 | Eisai Inc. | Phase 4 |
| Completed | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies NCT00038376 | M.D. Anderson Cancer Center | Phase 2 |